Department of Medical Microbiology and Immunology
Teresa Brooks has not added Biography.
If you are Teresa Brooks and would like to personalize this page please email our Author Liaison for assistance.
Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazines.
Bioorganic & medicinal chemistry letters Sep, 2002 | Pubmed ID: 12161135
Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes.
Journal of immunology (Baltimore, Md. : 1950) Aug, 2003 | Pubmed ID: 12902511
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Anti-cancer drugs Jan, 2004 | Pubmed ID: 15090742
Detection and identification of Legionella species from groundwaters.
Journal of toxicology and environmental health. Part A Oct 22-Nov 26, 2004 | Pubmed ID: 15371220
Discovery of a novel class of selective human CB1 inverse agonists.
Bioorganic & medicinal chemistry letters Feb, 2008 | Pubmed ID: 18083560
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
Bioorganic & medicinal chemistry letters Aug, 2009 | Pubmed ID: 19515560
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Bioorganic & medicinal chemistry letters Aug, 2009 | Pubmed ID: 19520572
Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor.
Bioorganic & medicinal chemistry letters Oct, 2009 | Pubmed ID: 19733067
Vibrio cholerae requires the type VI secretion system virulence factor VasX to kill Dictyostelium discoideum.
Infection and immunity Jul, 2011 | Pubmed ID: 21555399
VasH is a transcriptional regulator of the type VI secretion system functional in endemic and pandemic Vibrio cholerae.
Journal of bacteriology Dec, 2011 | Pubmed ID: 21949076
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
Bioorganic & medicinal chemistry letters Jan, 2012 | Pubmed ID: 22209458
Constitutive type VI secretion system expression gives Vibrio cholerae intra- and interspecific competitive advantages.
PloS one , 2012 | Pubmed ID: 23110230
Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Molecular cancer research : MCR Feb, 2013 | Pubmed ID: 23233484
Lytic activity of the Vibrio cholerae type VI secretion toxin VgrG-3 is inhibited by the antitoxin TsaB.
The Journal of biological chemistry Mar, 2013 | Pubmed ID: 23341465
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。